Delivering Pharma’s Mega-Projects in a Resource-Constrained World: Part Two
As pharmaceutical manufacturers push forward with massive capital expansion plans, challenges go beyond simply breaking ground on new facilities—it’s also managing the growing complexity, uncertainty,...
12 Touko 19min
Delivering Pharma’s Mega-Projects in a Resource-Constrained World: Part One
Rising capital investment in pharmaceutical manufacturing is pushing projects to unprecedented scale, but execution strategies haven’t fully kept pace. As companies commit billions to new facilities t...
5 Touko 31min
Annex 1 and the Shift to Proactive Sterile Manufacturing
Ever since the revised Annex 1 was published, drug makers have been navigating a broader transformation of sterile manufacturing that extends beyond compliance. Contamination control, in turn, is beco...
28 Huhti 25min
How U.S. Policy Is Reshaping Pharma Outsourcing
As the U.S. government pushes to reshore pharmaceutical manufacturing and rein in drug pricing, the implications for CDMOs and the broader outsourcing ecosystem are coming into sharper focus. While la...
21 Huhti 30min
Building the Foundation for Autonomous Bioprocessing
While fully autonomous bioprocessing is within reach, adoption remains gradual as manufacturers navigate challenges around data maturity, regulatory expectations, and operational readiness. As compani...
14 Huhti 22min
Reshoring APIs and Scaling Continuous Manufacturing for Generic Drug Supply
Generic medicines account for the vast majority of prescriptions in the U.S., yet much of their underlying supply chain remains heavily dependent on foreign-sourced active pharmaceutical ingredients (...
7 Huhti 16min
Engineering the Next Generation of ADCs
Antibody–drug conjugates (ADCs) are rapidly evolving from experimental hybrid molecules into mature, platform-driven therapeutics, with the global market projected to reach $36 billion by 2029. As pip...
31 Maalis 20min
Automating Cell and Gene Therapy Manufacturing for Scale
Cell and gene therapies (CGTs) have demonstrated transformative clinical potential, but manufacturing remains a major barrier to broader patient access. Highly manual, labor-intensive production proce...
24 Maalis 23min
